Delcath(DCTH)
QUEENSBURY, NY
PharmaceuticalFocus: Specialty Pharmaceuticals & Devices
Delcath is a life sciences company focused on Specialty Pharmaceuticals & Devices.
Neurology
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
1
Products & Portfolio (1)
Pipeline & Clinical Trials
Melphalan
Metastatic Liver CancerClinical Trials (1)
NCT01728051Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
N/ARegistry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepati
Hepatic Malignant Neoplasm Primary Non-ResectableClinical Trials (1)
NCT03266042Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
N/ANivolumab and Relatlimab
Metastatic MelanomaClinical Trials (1)
NCT07281924Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Phase 1/2Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab
Refractory Metastatic Colorectal CancerClinical Trials (1)
NCT06607458Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Phase 2Melphalan/HDS
Hepatocellular Carcinoma (HCC)Clinical Trials (1)
NCT02406508Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Phase 2Melphalan/HDS
Metastatic Uveal MelanomaClinical Trials (1)
NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Phase 2isolated perfusion
CancerClinical Trials (1)
NCT00096083Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Phase 2Melphalan/HDS followed by Physician's choice of SOC
Metastatic Breast Cancer in the LiverClinical Trials (1)
NCT06875128Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Phase 2Delcath Hepatic Delivery System
Hepatocellular CarcinomaClinical Trials (1)
NCT02415036Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Phase 2Melphalan/HDS
Bile Duct CancerClinical Trials (1)
NCT03086993Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Phase 2/3melphalan
Intraocular MelanomaClinical Trials (1)
NCT00324727Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Phase 3Melphalan
Metastatic Ocular MelanomaClinical Trials (1)
NCT05022901An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Phase 3Melphalan/HDS
Melanoma, OcularClinical Trials (1)
NCT02678572Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Phase 3Open Jobs (1)
Interview Prep Quick Facts
Portfolio: 1 approved product, 13 clinical trials
SEC Filings: 2 available
Open Roles: 1 active job
Portfolio Health
Growth1 (100%)
1 total products
Financials (FY2025)
Revenue
$37M1702%
R&D Spend
$14M(37%)21%
Net Income
-$26MCash
$32M